查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2148928

藥物釋放型支架市場規模、佔有率、成長率、全球產業分析、區域趨勢及2026年至2034年預測。

Drug Eluting Stent Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

藥物釋放型支架（DES）市場的成長要素

2025年全球藥物釋放型支架（DES）市場規模為69.4億美元，預計將從2026年的75.9億美元成長至2034年的155.2億美元，主要促進因素包括心血管疾病患病率的上升、微創介入心臟病學的日益普及以及支架技術的不斷進步。北美市場在2025年佔主導地位，市場佔有率達30.82%，這得益於有利的保險報銷政策、先進的醫療基礎設施以及對冠狀動脈介入治療日益成長的需求。

市場定義和範圍

藥物釋放型支架（DES）是一種半剛性管狀金屬醫療設備，其表面塗覆有治療藥物，植入後可緩慢釋放。這些藥物有助於預防血管再阻塞和動脈阻塞復發。現代DES技術致力於提高柔軟性和生物相容性，最佳化藥物傳輸系統，並降低血栓症風險。該市場涵蓋冠狀動脈和周邊血管支架置入術，涉及多種藥物、支架材料以及醫療領域的各類終端用戶。

藥物釋放型支架市場趨勢

生物可吸收聚合物塗層藥物釋放型支架的研發是市場發展的關鍵趨勢。這類支架旨在促進血管癒合，同時減少患者長期接觸聚合物。製造商正加大對超薄支架、先進藥物配方和改良型給藥系統的投入，以應對複雜病變並改善臨床療效。

此外，技術創新正在促進新一代 DES 產品的應用，這些產品具有更高的柔軟性、血管相容性和可控藥物釋放，使醫療保健專業人員能夠更有效地利用這些技術。

市場成長要素和趨勢

促進因素－心血管疾病負擔加重：冠狀動脈疾病、周邊動脈疾病、糖尿病、肥胖、吸菸和久坐的生活方式的盛行率不斷上升，促使對介入心臟病學和藥物釋放型支架的需求持續成長。

促進因素 - 先進的支架技術：持續的研究和開發促成了生物可吸收聚合物、超薄支架設計、改進的支架和先進的輸送系統的開發，從而支持在複雜的心血管治療中得到更廣泛的應用。

限制因素 - 產品召回：與部署問題、設備性能或其他安全問題相關的產品召回可能會削弱醫生的信心，增加監管壓力，並限制市場擴張。

市場機會－微創心血管療法：新興國家對微創手術的日益青睞以及心血管護理基礎設施的擴張，為藥物洗脫支架（DES）製造商帶來了機會。

挑戰－臨床和監管要求：製造商必須證明其產品的安全性、有效性、耐用性和臨床性能，同時滿足嚴格的監管要求。這可能導致研發成本增加和產品上市時間延長。

細分分析

按類型

根據適應症，支架市場可分為冠狀動脈支架和周邊血管支架。由於冠狀動脈疾病的高發生率以及藥物洗脫支架（DES）在經皮冠狀動脈介入治療（PCI）中的廣泛應用，冠狀動脈支架仍是主要細分市場。預計到2025年，冠狀動脈支架市佔率將達到80.1%。隨著周邊血管疾病盛行率的增加，周邊血管支架的重要性也預計將隨之成長。

藥物

市面上的抗血管內藥物包括Sirolimus、紫杉醇、佐他莫司、Everolimus等。Sirolimus因其降低血管再阻塞的療效而長期被廣泛應用，但隨著新一代支架的出現，佐他莫司和Everolimus因其更優的臨床療效和血管修復特性而得到更廣泛的應用。

不同類型的支架

支架材料包括鈷鉻合金、鉑鉻合金、鎳鈦合金等。鈷鉻合金因其柔軟性、生物相容性、耐用性以及與現代藥物釋放型支架（DES）設計的兼容性，仍然是主要材料。

最終用戶

由於冠狀動脈介入手術數量龐大，且醫院的醫療基礎設施不斷發展完善，因此醫院是主要的終端用戶群。此外，隨著某些心血管手術擴大轉向門診治療，專科診所和門診手術中心的重要性也日益凸顯。

區域分析

北美仍然是一個重要的區域市場，這得益於有利的報銷政策、先進的醫療保健基礎設施、心血管疾病的高發病率以及積極的研發活動。

在歐洲，由於聚合物技術的進步、新產品的批准以及下一代 DES 的日益普及，預計將穩定成長。

由於心血管疾病盛行率上升、醫療基礎設施改善以及先進心血管醫療設備的普及，亞太地區蘊藏著巨大的成長機會。在日本，預計到2025年，該市場規模將達到3.677億美元。

在拉丁美洲和中東及非洲地區，隨著醫療保健基礎設施和先進介入心臟病學的普及，預計市場將以適度的速度擴張。

競爭格局和主要公司

藥物洗脫支架（DES）市場相對集中，主要企業專注於產品創新、臨床研究、法規核准、地理擴張和策略投資。主要產業參與者包括波士頓科學公司、雅培公司、美敦力Medtronic、百多力公司、Terumo Corporation、微創醫療科技公司和薩哈賈南德醫療技術公司。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇

第4章：主要考慮因素

  • 主要地區和國家心血管疾病盛行率（2025 年）
  • 主要市場參與者推出新產品
  • 重大產業發展，例如併購（M&A）
  • 價格分析：依主要品牌、主要公司和主要地區分類。

第5章：全球藥物釋放型支架市場分析、洞察與預測（2021-2034年）

  • 主要發現與總結
  • 市場分析、洞察與預測：按類型
    • 冠狀動脈支架
    • 外周支架
  • 市場分析、洞察與預測：按支架類型分類
    • 鈷鉻合金
    • 鉑金鉻
    • 鎳鈦諾
    • 其他
  • 市場分析、洞察與預測：按藥物類型分類
    • Sirolimus
    • 紫杉醇
    • 佐他羅莫司
    • Everolimus
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院
    • 專科診所
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美藥物釋放型支架市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲藥物釋放型支架市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區藥物釋放型支架市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：2021-2034年拉丁美洲藥物釋放型支架市場分析、洞察與預測

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東和非洲藥物釋放型支架市場分析、洞察與預測

  • 國家
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 主要行業趨勢
  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Boston Scientific Corporation
    • Abbott
    • Medtronic
    • Biotronik
    • Terumo Corporation
    • MicroPort Scientific Corporation
    • Other Prominent Players

第12章 戰略建議

Product Code: FBI102612

Growth Factors of drug eluting stent (DES) Market

The global drug eluting stent (DES) market size was valued at USD 6.94 billion in 2025 and is projected to grow from USD 7.59 billion in 2026 to USD 15.52 billion by 2034, driven by the increasing prevalence of cardiovascular diseases, rising adoption of minimally invasive cardiovascular interventions, and continuous advancements in stent technologies. North America dominated the market with a 30.82% share in 2025, supported by favorable reimbursement policies, advanced healthcare infrastructure, and increasing demand for coronary interventions.

Market Definition and Scope

A drug eluting stent is a semi-rigid, tube-like metallic medical device coated with a therapeutic drug that is gradually released after implantation. The drug helps reduce restenosis and the recurrence of arterial blockages. Modern DES technologies focus on improved flexibility, biocompatibility, delivery systems, and reduced risks of thrombosis. The market covers coronary and peripheral stenting procedures and includes different drugs, scaffold materials, and healthcare end users.

Drug Eluting Stent Market Trends

The development of bioabsorbable polymer-coated drug eluting stents is an important market trend. These stents are designed to improve vessel healing while reducing long-term polymer exposure. Manufacturers are increasingly investing in ultrathin stents, advanced drug formulations, and improved delivery systems to address complex lesions and improve clinical outcomes.

Technological innovation is also encouraging healthcare providers to adopt newer-generation DES products that offer better flexibility, vessel compatibility, and controlled drug release.

Market Growth Factors and Dynamics

Driver - Rising Cardiovascular Disease Burden: The increasing prevalence of coronary artery disease, peripheral arterial disease, diabetes, obesity, smoking, and sedentary lifestyles is creating sustained demand for cardiovascular interventions and drug eluting stents.

Driver - Advanced Stent Technologies: Continuous research and development is leading to bioabsorbable polymers, ultrathin stent designs, improved scaffolds, and advanced delivery systems, supporting broader adoption in complex cardiovascular procedures.

Restraint - Product Recalls: Product recalls associated with deployment issues, device performance, or other safety concerns can affect physician confidence and increase regulatory pressure, limiting market expansion.

Market Opportunity - Minimally Invasive Cardiovascular Treatment: Increasing preference for minimally invasive procedures and the expansion of cardiovascular treatment infrastructure in emerging economies provide opportunities for DES manufacturers.

Challenge - Clinical and Regulatory Requirements: Manufacturers must demonstrate device safety, effectiveness, durability, and clinical performance while meeting stringent regulatory requirements, which can increase development costs and commercialization timelines.

Segmentation Analysis

By Type

Based on indication, the market is divided into coronary stenting and peripheral stenting. Coronary stenting remains the leading segment because of the widespread prevalence of coronary artery disease and the extensive use of DES in percutaneous coronary interventions. The coronary stenting segment accounted for 80.1% of the market in 2025. Peripheral stenting is expected to gain importance as peripheral vascular diseases become more prevalent.

By Drug

The market includes Sirolimus, Paclitaxel, Zotarolimus, Everolimus, and Others. Sirolimus has historically been widely used because of its effectiveness in reducing restenosis, while newer-generation stents increasingly use Zotarolimus and Everolimus because of their clinical performance and improved vessel healing characteristics.

By Scaffold

Scaffolds include cobalt-chromium, platinum-chromium, nitinol, and others. Cobalt-chromium remains a leading material because of its flexibility, biocompatibility, durability, and suitability for modern DES designs.

By End User

Hospitals represent a major end-user segment due to the high volume of coronary intervention procedures and increasing healthcare infrastructure. Specialty clinics and ambulatory surgical centers are also gaining importance as selected cardiovascular procedures increasingly shift toward outpatient settings.

Regional Analysis

North America remains the leading regional market, supported by favorable reimbursement policies, advanced healthcare infrastructure, cardiovascular disease prevalence, and significant research and development activities.

Europe is expected to maintain steady growth through advancements in polymer technology, new product approvals, and increasing adoption of newer-generation DES.

Asia Pacific offers significant growth opportunities due to rising cardiovascular disease prevalence, improving healthcare infrastructure, and increasing adoption of technologically advanced cardiovascular devices. Japan is expected to reach USD 367.7 million in 2025.

Latin America and the Middle East & Africa are expected to expand at moderate rates as healthcare infrastructure and access to advanced cardiovascular interventions continue to improve.

Competitive Landscape and Key Industry Players

The DES market is relatively consolidated, with major companies emphasizing product innovation, clinical research, regulatory approvals, geographic expansion, and strategic investments. Key industry players include Boston Scientific Corporation, Abbott, Medtronic, Biotronik, Terumo Corporation, MicroPort Scientific Corporation, and Sahajanand Medical Technologies.

Key Industry Developments

Recent industry developments have focused on shorter dual antiplatelet therapy options, advanced DES systems for complex lesions, expanded regulatory approvals, and commercialization of newer-generation stents. These developments reflect manufacturers' efforts to improve patient outcomes and broaden the clinical applications of DES technologies.

Future Outlook

The market is expected to benefit from increasing cardiovascular disease prevalence, rising healthcare expenditure, growing demand for minimally invasive interventions, and continued innovation in stent materials and drug-delivery technologies. Bioabsorbable polymers, ultrathin designs, and advanced scaffolds are likely to remain important areas of development through 2034.

Report Coverage

The Drug Eluting Stent market analysis covers market size and market value, segmentation by type, drug, scaffold, and end user, regional developments, market trends, growth drivers, restraints, opportunities, challenges, competitive strategies, key companies, and industry developments. The analysis provides an overview of the factors shaping demand for DES technologies across major healthcare markets.

Conclusion

The Drug Eluting Stent market is positioned for strong expansion, increasing from a market size of USD 6.94 billion in 2025 to USD 7.59 billion in 2026 and USD 15.52 billion by 2034. Rising cardiovascular disease prevalence and continuous innovation in stent design will remain major growth drivers. At the same time, product safety requirements and recalls present challenges for manufacturers. The development of bioabsorbable polymers, advanced scaffolds, and minimally invasive cardiovascular technologies is expected to create significant opportunities and strengthen the market outlook through 2034.

Unit Value (USD billion)

Segmentation By Type

  • Coronary Stenting
  • Peripheral Stenting

By Scaffold

  • Cobalt-Chromium
  • Platinum-Chromium
  • Nitinol
  • Others

By Drug

  • Sirolimus
  • Paclitaxel
  • Zotarolimus
  • Everolimus
  • Others

By End User

  • Hospitals
  • Specialty Clinics

By Geography

  • North America (the U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Cardiovascular Diseases, By Key Regions/ Key Countries, 2025
  • 4.2. New Product Launches, By Key Market Players
  • 4.3. Key Industry Developments, Such as Mergers & Acquisitions
  • 4.4. Pricing Analysis, By Key Brands, Key Players/ Key Regions

5. Global Drug Eluting Stents (DES) Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. Coronary Stenting
    • 5.2.2. Peripheral Stenting
  • 5.3. Market Analysis, Insights and Forecast - By Scaffold
    • 5.3.1. Cobalt-Chromium
    • 5.3.2. Platinum-Chromium
    • 5.3.3. Nitinol
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Drug
    • 5.4.1. Sirolimus
    • 5.4.2. Paclitaxel
    • 5.4.3. Zotarolimus
    • 5.4.4. Everolimus
    • 5.4.5. Others
  • 5.5. Market Analysis, Insights and Forecast - By End User
    • 5.5.1. Hospitals
    • 5.5.2. Specialty Clinics
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Drug Eluting Stents (DES) Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. Coronary Stenting
    • 6.2.2. Peripheral Stenting
  • 6.3. Market Analysis, Insights and Forecast - By Scaffold
    • 6.3.1. Cobalt-Chromium
    • 6.3.2. Platinum-Chromium
    • 6.3.3. Nitinol
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Drug
    • 6.4.1. Sirolimus
    • 6.4.2. Paclitaxel
    • 6.4.3. Zotarolimus
    • 6.4.4. Everolimus
    • 6.4.5. Others
  • 6.5. Market Analysis, Insights and Forecast - By End User
    • 6.5.1. Hospitals
    • 6.5.2. Specialty Clinics
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Drug Eluting Stents (DES) Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. Coronary Stenting
    • 7.2.2. Peripheral Stenting
  • 7.3. Market Analysis, Insights and Forecast - By Scaffold
    • 7.3.1. Cobalt-Chromium
    • 7.3.2. Platinum-Chromium
    • 7.3.3. Nitinol
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Drug
    • 7.4.1. Sirolimus
    • 7.4.2. Paclitaxel
    • 7.4.3. Zotarolimus
    • 7.4.4. Everolimus
    • 7.4.5. Others
  • 7.5. Market Analysis, Insights and Forecast - By End User
    • 7.5.1. Hospitals
    • 7.5.2. Specialty Clinics
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Spain
    • 7.6.5. Italy
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Drug Eluting Stents (DES) Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. Coronary Stenting
    • 8.2.2. Peripheral Stenting
  • 8.3. Market Analysis, Insights and Forecast - By Scaffold
    • 8.3.1. Cobalt-Chromium
    • 8.3.2. Platinum-Chromium
    • 8.3.3. Nitinol
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Drug
    • 8.4.1. Sirolimus
    • 8.4.2. Paclitaxel
    • 8.4.3. Zotarolimus
    • 8.4.4. Everolimus
    • 8.4.5. Others
  • 8.5. Market Analysis, Insights and Forecast - By End User
    • 8.5.1. Hospitals
    • 8.5.2. Specialty Clinics
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Drug Eluting Stents (DES) Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. Coronary Stenting
    • 9.2.2. Peripheral Stenting
  • 9.3. Market Analysis, Insights and Forecast - By Scaffold
    • 9.3.1. Cobalt-Chromium
    • 9.3.2. Platinum-Chromium
    • 9.3.3. Nitinol
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Drug
    • 9.4.1. Sirolimus
    • 9.4.2. Paclitaxel
    • 9.4.3. Zotarolimus
    • 9.4.4. Everolimus
    • 9.4.5. Others
  • 9.5. Market Analysis, Insights and Forecast - By End User
    • 9.5.1. Hospitals
    • 9.5.2. Specialty Clinics
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Drug Eluting Stents (DES) Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. Coronary Stenting
    • 10.2.2. Peripheral Stenting
  • 10.3. Market Analysis, Insights and Forecast - By Scaffold
    • 10.3.1. Cobalt-Chromium
    • 10.3.2. Platinum-Chromium
    • 10.3.3. Nitinol
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Drug
    • 10.4.1. Sirolimus
    • 10.4.2. Paclitaxel
    • 10.4.3. Zotarolimus
    • 10.4.4. Everolimus
    • 10.4.5. Others
  • 10.5. Market Analysis, Insights and Forecast - By End User
    • 10.5.1. Hospitals
    • 10.5.2. Specialty Clinics
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.6.1. GCC Countries
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Company Profiles
    • 11.3.1. Boston Scientific Corporation
      • 11.3.1.1. Overview,
      • 11.3.1.2. Products,
      • 11.3.1.3. SWOT,
      • 11.3.1.4. Recent Developments,
      • 11.3.1.5. Strategies,
      • 11.3.1.6. Financials (based on availability)
    • 11.3.2. Abbott
      • 11.3.2.1. Overview,
      • 11.3.2.2. Products,
      • 11.3.2.3. SWOT,
      • 11.3.2.4. Recent Developments,
      • 11.3.2.5. Strategies,
      • 11.3.2.6. Financials (based on availability)
    • 11.3.3. Medtronic
      • 11.3.3.1. Overview,
      • 11.3.3.2. Products,
      • 11.3.3.3. SWOT,
      • 11.3.3.4. Recent Developments,
      • 11.3.3.5. Strategies,
      • 11.3.3.6. Financials (based on availability)
    • 11.3.4. Biotronik
      • 11.3.4.1. Overview,
      • 11.3.4.2. Products,
      • 11.3.4.3. SWOT,
      • 11.3.4.4. Recent Developments,
      • 11.3.4.5. Strategies,
      • 11.3.4.6. Financials (based on availability)
    • 11.3.5. Terumo Corporation
      • 11.3.5.1. Overview,
      • 11.3.5.2. Products,
      • 11.3.5.3. SWOT,
      • 11.3.5.4. Recent Developments,
      • 11.3.5.5. Strategies,
      • 11.3.5.6. Financials (based on availability)
    • 11.3.6. MicroPort Scientific Corporation
      • 11.3.6.1. Overview,
      • 11.3.6.2. Products,
      • 11.3.6.3. SWOT,
      • 11.3.6.4. Recent Developments,
      • 11.3.6.5. Strategies,
      • 11.3.6.6. Financials (based on availability)
    • 11.3.7. Other Prominent Players
      • 11.3.7.1. Overview,
      • 11.3.7.2. Products,
      • 11.3.7.3. SWOT,
      • 11.3.7.4. Recent Developments,
      • 11.3.7.5. Strategies,
      • 11.3.7.6. Financials (based on availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Type, 2021-2034
  • Table 2: Global Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Scaffold, 2021-2034
  • Table 3: Global Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Drug, 2021-2034
  • Table 4: Global Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 5: Global Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 6: North America Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Type, 2021-2034
  • Table 7: North America Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Scaffold, 2021-2034
  • Table 8: North America Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Drug, 2021-2034
  • Table 9: North America Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 10: North America Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 11: Europe Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Type, 2021-2034
  • Table 12: Europe Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Scaffold, 2021-2034
  • Table 13: Europe Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Drug, 2021-2034
  • Table 14: Europe Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 15: Europe Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Type, 2021-2034
  • Table 17: Asia Pacific Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Scaffold, 2021-2034
  • Table 18: Asia Pacific Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Drug, 2021-2034
  • Table 19: Asia Pacific Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 20: Asia Pacific Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Type, 2021-2034
  • Table 22: Latin America Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Scaffold, 2021-2034
  • Table 23: Latin America Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Drug, 2021-2034
  • Table 24: Latin America Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 25: Latin America Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Type, 2021-2034
  • Table 27: Middle East & Africa Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Scaffold, 2021-2034
  • Table 28: Middle East & Africa Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by Drug, 2021-2034
  • Table 29: Middle East & Africa Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 30: Middle East & Africa Drug Eluting Stents (DES) Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Drug Eluting Stents (DES) Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Drug Eluting Stents (DES) Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Drug Eluting Stents (DES) Market Forecast (US$ Mn), by Coronary Stenting, 2021-2034
  • Figure 4: Global Drug Eluting Stents (DES) Market Forecast (US$ Mn), by Peripheral Stenting, 2021-2034
  • Figure 5: Global Drug Eluting Stents (DES) Market Value Share (%), by Scaffold, 2025 & 2034
  • Figure 6: Global Drug Eluting Stents (DES) Market Forecast (US$ Mn), by Cobalt-Chromium, 2021-2034
  • Figure 7: Global Drug Eluting Stents (DES) Market Forecast (US$ Mn), by Platinum-Chromium, 2021-2034
  • Figure 8: Global Drug Eluting Stents (DES) Market Forecast (US$ Mn), by Nitinol, 2021-2034
  • Figure 9: Global Drug Eluting Stents (DES) Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 10: Global Drug Eluting Stents (DES) Market Value Share (%), by Drug, 2025 & 2034
  • Figure 11: Global Drug Eluting Stents (DES) Market Forecast (US$ Mn), by Sirolimus, 2021-2034
  • Figure 12: Global Drug Eluting Stents (DES) Market Forecast (US$ Mn), by Paclitaxel, 2021-2034
  • Figure 13: Global Drug Eluting Stents (DES) Market Forecast (US$ Mn), by Zotarolimus, 2021-2034
  • Figure 14: Global Drug Eluting Stents (DES) Market Forecast (US$ Mn), by Everolimus, 2021-2034
  • Figure 15: Global Drug Eluting Stents (DES) Market Forecast (US$ Mn), by Mod5, 2021-2034
  • Figure 16: Global Drug Eluting Stents (DES) Market Value Share (%), by End User, 2025 & 2034
  • Figure 17: Global Drug Eluting Stents (DES) Market Forecast (US$ Mn), by Hospitals, 2021-2034
  • Figure 18: Global Drug Eluting Stents (DES) Market Forecast (US$ Mn), by Specialty Clinics, 2021-2034
  • Figure 19: Global Drug Eluting Stents (DES) Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 20: North America Drug Eluting Stents (DES) Market Value (US$ Mn), by Type, 2025 & 2034
  • Figure 21: North America Drug Eluting Stents (DES) Market Value Share (%), by Type, 2025
  • Figure 22: North America Drug Eluting Stents (DES) Market Value (US$ Mn), by Scaffold, 2025 & 2034
  • Figure 23: North America Drug Eluting Stents (DES) Market Value Share (%), by Scaffold, 2025
  • Figure 24: North America Drug Eluting Stents (DES) Market Value (US$ Mn), by Drug, 2025 & 2034
  • Figure 25: North America Drug Eluting Stents (DES) Market Value Share (%), by Drug, 2025
  • Figure 26: North America Drug Eluting Stents (DES) Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 27: North America Drug Eluting Stents (DES) Market Value Share (%), by End User, 2025
  • Figure 28: North America Drug Eluting Stents (DES) Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 29: North America Drug Eluting Stents (DES) Market Value Share (%), By Country, 2025
  • Figure 30: Europe Drug Eluting Stents (DES) Market Value (US$ Mn), by Type, 2025 & 2034
  • Figure 31: Europe Drug Eluting Stents (DES) Market Value Share (%), by Type, 2025
  • Figure 32: Europe Drug Eluting Stents (DES) Market Value (US$ Mn), by Scaffold, 2025 & 2034
  • Figure 33: Europe Drug Eluting Stents (DES) Market Value Share (%), by Scaffold, 2025
  • Figure 34: Europe Drug Eluting Stents (DES) Market Value (US$ Mn), by Drug, 2025 & 2034
  • Figure 35: Europe Drug Eluting Stents (DES) Market Value Share (%), by Drug, 2025
  • Figure 36: Europe Drug Eluting Stents (DES) Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 37: Europe Drug Eluting Stents (DES) Market Value Share (%), by End User, 2025
  • Figure 38: Europe Drug Eluting Stents (DES) Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 39: Europe Drug Eluting Stents (DES) Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 40: Asia Pacific Drug Eluting Stents (DES) Market Value (US$ Mn), by Type, 2025 & 2034
  • Figure 41: Asia Pacific Drug Eluting Stents (DES) Market Value Share (%), by Type, 2025
  • Figure 42: Asia Pacific Drug Eluting Stents (DES) Market Value (US$ Mn), by Scaffold, 2025 & 2034
  • Figure 43: Asia Pacific Drug Eluting Stents (DES) Market Value Share (%), by Scaffold, 2025
  • Figure 44: Asia Pacific Drug Eluting Stents (DES) Market Value (US$ Mn), by Drug, 2025 & 2034
  • Figure 45: Asia Pacific Drug Eluting Stents (DES) Market Value Share (%), by Drug, 2025
  • Figure 46: Asia Pacific Drug Eluting Stents (DES) Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 47: Asia Pacific Drug Eluting Stents (DES) Market Value Share (%), by End User, 2025
  • Figure 48: Asia Pacific Drug Eluting Stents (DES) Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 49: Asia Pacific Drug Eluting Stents (DES) Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 50: Latin America Drug Eluting Stents (DES) Market Value (US$ Mn), by Type, 2025 & 2034
  • Figure 51: Latin America Drug Eluting Stents (DES) Market Value Share (%), by Type, 2025
  • Figure 52: Latin America Drug Eluting Stents (DES) Market Value (US$ Mn), by Scaffold, 2025 & 2034
  • Figure 53: Latin America Drug Eluting Stents (DES) Market Value Share (%), by Scaffold, 2025
  • Figure 54: Latin America Drug Eluting Stents (DES) Market Value (US$ Mn), by Drug, 2025 & 2034
  • Figure 55: Latin America Drug Eluting Stents (DES) Market Value Share (%), by Drug, 2025
  • Figure 56: Latin America Drug Eluting Stents (DES) Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 57: Latin America Drug Eluting Stents (DES) Market Value Share (%), by End User, 2025
  • Figure 58: Latin America Drug Eluting Stents (DES) Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 59: Latin America Drug Eluting Stents (DES) Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 60: Middle East & Africa Drug Eluting Stents (DES) Market Value (US$ Mn), by Type, 2025 & 2034
  • Figure 61: Middle East & Africa Drug Eluting Stents (DES) Market Value Share (%), by Type, 2025
  • Figure 62: Middle East & Africa Drug Eluting Stents (DES) Market Value (US$ Mn), by Scaffold, 2025 & 2034
  • Figure 63: Middle East & Africa Drug Eluting Stents (DES) Market Value Share (%), by Scaffold, 2025
  • Figure 64: Middle East & Africa Drug Eluting Stents (DES) Market Value (US$ Mn), by Drug, 2025 & 2034
  • Figure 65: Middle East & Africa Drug Eluting Stents (DES) Market Value Share (%), by Drug, 2025
  • Figure 66: Middle East & Africa Drug Eluting Stents (DES) Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 67: Middle East & Africa Drug Eluting Stents (DES) Market Value Share (%), by End User, 2025
  • Figure 68: Middle East & Africa Drug Eluting Stents (DES) Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 69: Middle East & Africa Drug Eluting Stents (DES) Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 70: Global Drug Eluting Stents (DES) Market Share (%), By Company, 2025